Press releases
- Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
- Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
- Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
- Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
- Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
- Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
- Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
More ▼
Key statistics
As of last trade, Arrowhead Pharmaceuticals Inc (HDP1:BER) traded at 33.70, 28.07% above the 52 week low of 26.31 set on Jun 17, 2022.
52-week range
Markit short selling activity
Open | 33.70 |
---|---|
High | 33.70 |
Low | 33.70 |
Bid | 33.46 |
Offer | 33.96 |
Previous close | 31.74 |
Average volume | 31.60 |
---|---|
Shares outstanding | 106.71m |
Free float | 103.29m |
P/E (TTM) | -- |
Market cap | 3.95bn USD |
EPS (TTM) | -1.68 USD |
Data delayed at least 15 minutes, as of Feb 03 2023 07:08 GMT.
More ▼